VistaGen Therapeutics, Inc. (NASDAQ:VTGN) Receives Consensus Rating of “Reduce” from Analysts

Shares of VistaGen Therapeutics, Inc. (NASDAQ:VTGN) have received an average recommendation of “Reduce” from the five research firms that are currently covering the company, Marketbeat reports. One research analyst has rated the stock with a sell rating and four have given a hold rating to the company. The average twelve-month price target among brokerages that have covered the stock in the last year is $0.95.

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of VistaGen Therapeutics in a research note on Wednesday, June 3rd.

VistaGen Therapeutics Stock Up 1.5%

Shares of VTGN stock traded up $0.00 during mid-day trading on Thursday, reaching $0.25. The stock had a trading volume of 157,697 shares, compared to its average volume of 1,410,047. VistaGen Therapeutics has a one year low of $0.20 and a one year high of $5.14. The firm has a market cap of $10.13 million, a PE ratio of -0.13 and a beta of 0.40. The firm’s 50 day simple moving average is $0.45 and its 200 day simple moving average is $0.55.

VistaGen Therapeutics (NASDAQ:VTGN) last released its quarterly earnings data on Monday, June 15th. The company reported ($0.37) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.34) by ($0.03). The firm had revenue of $0.38 million for the quarter, compared to the consensus estimate of $0.40 million. VistaGen Therapeutics had a negative net margin of 5,487.01% and a negative return on equity of 133.02%. During the same quarter in the prior year, the firm posted ($1.67) earnings per share. Sell-side analysts forecast that VistaGen Therapeutics will post -1.32 earnings per share for the current fiscal year.

Hedge Funds Weigh In On VistaGen Therapeutics

Hedge funds and other institutional investors have recently made changes to their positions in the business. Virtu Financial LLC bought a new stake in VistaGen Therapeutics in the fourth quarter valued at about $25,000. Cubist Systematic Strategies LLC acquired a new stake in VistaGen Therapeutics during the first quarter valued at approximately $25,000. Schonfeld Strategic Advisors LLC acquired a new stake in VistaGen Therapeutics during the third quarter valued at approximately $39,000. Seven Fleet Capital Management LP bought a new stake in shares of VistaGen Therapeutics in the 4th quarter valued at approximately $42,000. Finally, Tudor Investment Corp ET AL bought a new stake in shares of VistaGen Therapeutics in the 4th quarter valued at approximately $50,000. 78.39% of the stock is owned by institutional investors.

About VistaGen Therapeutics

VistaGen Therapeutics, Inc (NASDAQ:VTGN) is a clinical-stage biopharmaceutical company dedicated to the discovery and development of next-generation medicines for central nervous system disorders. Incorporated in Delaware in 1998 and headquartered in South San Francisco, California, VistaGen applies advanced human pluripotent stem cell technologies to accelerate drug candidate validation and optimization. The company’s core focus is on addressing unmet medical needs in major depressive disorder, neuropathic pain and dermatological conditions.

The company’s lead candidate, AV-101, is an oral prodrug designed to modulate glutamatergic neurotransmission via the N-methyl-D-aspartate (NMDA) receptor pathway, with clinical programs targeting major depressive disorder and neuropathic pain.